Maja Sirovica

Dr. Maja Sirovica

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 May 2023 in Antibodies
Verified
Journal Article
Open access
PDF file
VPVedran Premužić
Vedran Premužić
RSRanko Stevanović
Ranko Stevanović
Tatjana Vilibic-CavlekTatjana Vilibic-Cavlek
Tatjana Vilibic-Cavlek
MSMaja Sirovica
Maja Sirovica
SSSara Stalman
Sara Stalman
Bojan JelakovićBojan Jelaković
Bojan Jelaković
Background: The effectiveness of the COVID-19 vaccine may differ in hemodialysis patients. The aim of this prospective multicenter study was to determine the degree of serological response to the SARS-CoV-2 vaccine in the population of dialysis patients and its association with later SARS-CoV-2 infections. Methods: A blood sample was taken for the determination of COVID-19 serological status (IgG antibodies) in 706 dialysis patients 16 weeks after vaccination with the second dose (Pfizer-BioNTech). Results: Only 314 (44.5%) hemodialyzed patients had a satisfactory response to the COVID-19 vaccine. Eighty-two patients (11.6%) had a borderline response, while 310 patients (43.9%) had an unsatisfactory (negative) post-vaccinal antibody titer. A longer dialysis vintage had an increased odds ratio (OR) of 1.01 for the occurrence of COVID-19 positivity after vaccination. In the group of subsequently positive patients, 28 patients (13.6%) died from complications of COVID-19. We have found differences in mean survival time between patients with and without appropriate responses to vaccination in favor of patients with a satisfactory serological response. Conclusions: The results showed that the dialysis population will not have the same serological response to the vaccine as the general population. The majority of dialysis patients did not develop a severe clinical picture or die at the time of positivity for COVID-19.

4 January 2024 in Diabetology
Verified
Journal Article
Open access
PDF file
MMMartina Matovinović
Martina Matovinović
Andrej BelančićAndrej Belančić
Andrej Belančić
Juraj JugJuraj Jug
Juraj Jug
FMFilip Mustač
Filip Mustač
MSMaja Sirovica
Maja Sirovica
MBMartina Lovrić Benčić
Martina Lovrić Benčić
Background: Diabetes is the primary contributor to cardiovascular disease risk, and when combined with obesity, it further underscores the significance of cardiovascular risk assessment. Methods: A retrospective study of 64 patients with type 2 diabetes (T2D) and obesity on once-weekly subcutaneous semaglutide stratified by cardiovascular risk categories determined using the SCORE2/SCORE2-OP, SCORE2-Diabetes, and ASCVD score calculations. We compare the differences between groups (ASCVD: low + borderline + intermediate versus high-risk group; SCORE2/SCORE2-OP: low + moderate versus high + very high-risk group and SCORE2-Diabetes: low + moderate versus high + very high-risk group) in terms of change from baseline in body mass index (BMI) and HbA1c and weight loss outcomes. Results: Patients in the high-risk group, according to ASCVD risk score, had statistically better results in weight loss ≥ 3%, ≥5%, and ≥10% compared to ASCVD low + borderline + intermediate and without difference regarding HbA1c. According to SCORE2/SCORE2-OP, the high + very high-risk group had statistically better HbA1c and weight loss results but only for ≥5% versus the low + moderate risk group. Based on the score SCORE2-Diabetes, the high + very high-risk group had statistically significant better results in lowering HbA1c and weight loss but only for ≥5% versus the low + moderate risk group. Conclusions: To the best of our knowledge, this study represents the initial investigation linking glycemic control and weight reduction outcomes in individuals with T2D and obesity treated with once-weekly semaglutide stratified by cardiovascular risk categories determined using the SCORE2/SCORE2-OP, SCORE2-Diabetes and ASCVD score calculations.


1 November 2022 in Cardiologia Croatica
Verified
Journal Article
Open access
Rea LevickiRea Levicki
Rea Levicki
TBTamara Božina
Tamara Božina
NBNada Božina
Nada Božina
MSMaja Sirovica
Maja Sirovica
DMDubravka Memić
Dubravka Memić
MLMartina Lovrić-Benčić
Martina Lovrić-Benčić